Taysha Gene Therapies annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Taysha Gene Therapies Depreciation & Amortization Growth & History (TSHA)
Taysha Gene Therapies's depreciation and amortization was $1.1M for fiscal 2025.
View full Taysha Gene Therapies company overviewTaysha Gene Therapies annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.1M | −$100,000 | −8.03% |
| 2024 | 2024-12-31 | $1.2M | −$126,000 | −9.19% |
| 2023 | 2023-12-31 | $1.4M | $199,000 | +16.98% |
| 2022 | 2022-12-31 | $1.2M | $680,000 | +138.21% |
| 2021 | 2021-12-31 | $492,000 | $483,000 | +5366.67% |
| 2020 | 2020-12-31 | $9,000 | — | — |
Taysha Gene Therapies quarterly depreciation and amortization
Q4.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $400,000 | $100,000 | +33.33% |
| Q1 2026 | 2026-03-31 | $295,000 | $12,000 | +4.24% |
| Q4 2025 | 2025-12-31 | $299,000 | — | — |
| Q3 2025 | 2025-09-30 | $200,000 | −$100,000 | −33.33% |
| Q2 2025 | 2025-06-30 | $300,000 | $0 | 0.00% |
| Q1 2025 | 2025-03-31 | $283,000 | −$42,000 | −12.92% |
| Q3 2024 | 2024-09-30 | $300,000 | $0 | 0.00% |
| Q2 2024 | 2024-06-30 | $300,000 | −$100,000 | −25.00% |
| Q1 2024 | 2024-03-31 | $325,000 | −$6,000 | −1.81% |
| Q3 2023 | 2023-09-30 | $300,000 | $0 | 0.00% |
| Q2 2023 | 2023-06-30 | $400,000 | $100,000 | +33.33% |
| Q1 2023 | 2023-03-31 | $331,000 | $71,000 | +27.31% |
| Q3 2022 | 2022-09-30 | $300,000 | $100,000 | +50.00% |
| Q2 2022 | 2022-06-30 | $300,000 | $215,000 | +252.94% |
| Q1 2022 | 2022-03-31 | $260,000 | $228,000 | +712.50% |
| Q3 2021 | 2021-09-30 | $200,000 | $197,000 | +6566.67% |
| Q2 2021 | 2021-06-30 | $85,000 | $85,000 | — |
| Q1 2021 | 2021-03-31 | $32,000 | $32,000 | — |
| Q3 2020 | 2020-09-30 | $3,000 | — | — |
| Q2 2020 | 2020-06-30 | $0 | — | — |
| Q1 2020 | 2020-03-31 | $0 | — | — |
| Q4 2019 | 2019-12-31 | $0 | — | — |
Taysha Gene Therapies depreciation and amortization trends
Over the last five fiscal years, Taysha Gene Therapies's depreciation and amortization increased from $9,000 to $1.1M, a change of $1.1M. The latest reported quarter, Q2 2026, shows $400,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Taysha Gene Therapies source filings ↗